BAXDELA (delafloxacin meglumine) by CorMedix is 12. Approved for skin structure infections (absssi) caused by the following susceptible microorganisms: staphylococcus aureus (including methicillin-resistant [mrsa], methicillin-susceptible [mssa] isolates), staphylococcus haemolyticus and 17 more indications. First approved in 2017.
Drug data last refreshed 10h ago · AI intelligence enriched 4d ago
BAXDELA is a fluoroquinolone antibiotic (delafloxacin meglumine) administered intravenously for acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive and Gram-negative organisms including MRSA. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, with activity best correlated to the f AUC/MIC ratio. The drug demonstrated no clinically relevant QT prolongation and no phototoxic potential in clinical studies.
BAXDELA is at peak lifecycle stage with moderate revenue, suggesting stable commercial operations but limited near-term growth opportunities.
12.1 Mechanism of Action BAXDELA is an antibacterial drug [see ] . 12.2 Pharmacodynamics The antibacterial activity of delafloxacin appears to best correlate with the ratio of area under the concentration-time curve of free delafloxacin to minimal inhibitory concentration ( f AUC/MIC) for…
Worked on BAXDELA at CorMedix? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moBAXDELA is a peak-stage product at CorMedix with limited job postings, suggesting a mature, stable team focused on defending market share against entrenched competitors. Roles available are primarily in commercial execution and market access, offering experience in competitive antibiotic positioning but limited growth upside given approaching LOE.